Document Detail


Efficacy and safety evaluation of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GISTs).
MedLine Citation:
PMID:  22889747     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND AND OBJECTIVE: Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GISTs). To evaluate the efficacy and safety of two dose of imatinib treatment for patients with GISTs, a meta-analysis was performed. METHODS: Electronic search of the PubMed and EMBASE, which have articles published between 1980 and February 2012, was conducted to select studies for this meta-analysis. RESULTS: Five articles with a total number 1861 of advanced GISTs patients were involved in this meta-analysis. There was a slight but significant 2-year PFS advantage with high-dose group (OR=1.25, 95% CIs=1.03-1.52, P=0.03), but not in the 2-year OS (OR=1.02, 95% CIs=0.84-1.24, P=0.87), CR (OR=1.02, 95% CIs=0.66-1.58, P=0.93), and PR (OR=1.13, 95% CIs=0.94-1.36, P=0.20). In safety, the high-dose group increased the incidence of above grade 3 toxicity (OR=2.05, 95% CIs=1.70-2.48, P<0.00001), particular in the blood toxicity, skin disorders, nausea and so on. CONCLUSIONS: This analysis confirms a slight 2-year PFS advantage of high-dose imatinib, but imatinib dose escalation could not lead to any other major clinical benefits, and brought more toxic effects for patients.
Authors:
Ping Yang; Bo Chen; Yong Zhou; Xiao-Ting Wu
Related Documents :
11751017 - Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacr...
10447577 - Topical dmso treatment for pegylated liposomal doxorubicin-induced palmar-plantar eryth...
11531287 - Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comp...
7980307 - The evidence for increasing cytotoxic dose intensity in the treatment of advanced ovari...
23828187 - Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against...
9349927 - Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-10
Journal Detail:
Title:  Clinics and research in hepatology and gastroenterology     Volume:  -     ISSN:  2210-741X     ISO Abbreviation:  Clin Res Hepatol Gastroenterol     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101553659     Medline TA:  Clin Res Hepatol Gastroenterol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier Masson SAS.
Affiliation:
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, 37, Guo Xue Road, Chengdu 610041, Sichuan Province, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stat3 Contributes to Indoxyl Sulfate-Induced Inflammatory and Fibrotic Gene Expression and Cellular ...
Next Document:  Aberrant expression of Wnt and Notch signal pathways in Barrett's esophagus.